ExpreS2ion Biotechnologies – Presentation of H1 2022 - 18.08.2022
– HC Andersen Capital
ExpreS2ion Biotechnologies expects to announce its half-year report for 2022 on 18th August 2022. You can meet and ask questions to the company’s CEO Bent Frandsen and CFO Keith Alexander, who will present the results in a live event on the 18th of August at 2.00 PM.
ExpreS2ion Biotech raised new capital in Q1 2022 to ensure financial flexibility, implying that the balance side should draw less attention. Besides the financial results for H1 2022, updates on the late-stage COVID-19 candidate should draw attention, especially in the light of new variants that seem to create a new wave of infections. Bavarian Nordic, the partner of the COVID-19 vaccine candidate, has announced that the trial will be initiated in August 2022.
ExpreS2ion Biotech is a Danish biotech company that focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system. Currently, the company has a late-stage pipeline on vaccines against COVID-19 and an early-stage pipeline for breast cancer, influenza, and malaria.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a DigitalIR/Corporate Visibility agreement.